Breaking News

Today Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
Options	Early notable gainers among liquid option names on May 20th » 09:55 05/20/22 05/20 09:55 05/20/22 09:55 MTCH Match Group $77.57 / +2.53 (+3.37%) , FTNT Fortinet $285.73 / +10.72 (+3.90%) , VFC VF Corp. $46.63 / +2 (+4.48%) , NOW ServiceNow $437.11 / +10.06 (+2.36%) , PFE Pfizer $51.85 / +1.195 (+2.36%) Notable gainers among… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options VFC PFE NOW MTCH FTNT VFC VF Corp. $46.63 / +2 (+4.48%) 03/10/22 Jerash Holdings to manufacture clothing for Timberland 01/11/22 VF Corp. names Nicole Otto as Global Brand President, The North Face PFE Pfizer $51.85 / +1.195 (+2.36%) 05/17/22 Pfizer, BioNTech receive FDA emergency use authorization for child booster 05/17/22 FDA expands eligibility for Pfizer-BioNTech booster to kids 5-11 years old 05/16/22 Mirati Therapeutics appoints Laurie Stelzer as CFO 05/13/22 Pfizer EVP Carapezzi sells 32,908 common shares NOW ServiceNow $437.11 / +10.06 (+2.36%) 05/16/22 Lone Pine adds TSMC in Q1, exits KE Holdings and Adobe 05/11/22 ServiceNow launches new solutions built on Now Platform 04/19/22 Tenable Holdings announces enhancements to partnership with ServiceNow 03/30/22 ServiceNow says ServiceNow NSC gets DoD IL5 'Provisional Authorization' MTCH Match Group $77.57 / +2.53 (+3.37%) 07:29 Today Match Group withdraws request for temporary restraining order against Google 05/09/22 Match Group files lawsuit against Google over unlawful billing mandates 05/03/22 Match Group says Shar to step down as CEO, Bernard Kim to succeed 05/03/22 Match Group names Bernard Kim as CEO FTNT Fortinet $285.73 / +10.72 (+3.90%) 05/04/22 Fortinet announces suite of FortiGate appliances 04/14/22 Fortinet, PGA Tour Canada announce long-term partnership 04/12/22 Fortinet launches Security Awareness and Training service 04/04/22 Fortinet announces release of FortiOS 7.2 MTCH FTNT VFC NOW PFE MTCH Match Group $77.57 / +2.53 (+3.37%) 05/10/22 Piper Sandler Match Group suit against Google not surprising, says Piper Sandler 05/09/22 Wells Fargo Wells Fargo upgrades Match Group to Overweight, lowers price target to $115 05/09/22 Wells Fargo Match Group upgraded to Overweight from Equal Weight at Wells Fargo 05/05/22 RBC Capital Match Group price target lowered to $115 from $150 at RBC Capital FTNT Fortinet $285.73 / +10.72 (+3.90%) 05/12/22 BMO Capital Fortinet price target lowered to $325 from $360 at BMO Capital 05/11/22 Daiwa Fortinet upgraded to Buy from Outperform at Daiwa 05/11/22 Deutsche Bank Fortinet price target lowered to $300 from $320 at Deutsche Bank 05/11/22 KeyBanc Fortinet price target lowered to $353 from $410 at KeyBanc VFC VF Corp. $46.63 / +2 (+4.48%) 08:25 Today Wedbush VF Corp. price target lowered to $50 from $61 at Wedbush 07:38 Today Credit Suisse VF Corp. price target lowered to $61 from $81 at Credit Suisse 07:15 Today Stifel VF Corp. price target lowered to $42 from $74 at Stifel 07:00 Today Baird VF Corp. price target lowered to $60 from $80 at Baird NOW ServiceNow $437.11 / +10.06 (+2.36%) 05/18/22 Wells Fargo ServiceNow initiated with an Overweight at Wells Fargo 05/10/22 Truist ServiceNow price target lowered to $600 from $700 at Truist 04/28/22 BMO Capital ServiceNow price target raised to $595 from $570 at BMO Capital 04/28/22 Morgan Stanley ServiceNow price target lowered to $745 from $810 at Morgan Stanley PFE Pfizer $51.85 / +1.195 (+2.36%) 05/11/22 H.C. Wainwright Biohaven Pharmaceutical downgraded to Neutral from Buy at H.C. Wainwright 05/11/22 Wedbush Global Blood Therapeutics added to Best Ideas List at Wedbush 05/05/22 Stifel Stifel keeps Buy rating on Arvinas, lowers price target to $82 05/04/22 Wells Fargo Pfizer price target lowered to $55 from $60 at Wells Fargo VFC PFE NOW MTCH FTNT VFC VF Corp. $46.63 / +2 (+4.48%) 05/19/22 VF Corp. sees FY23 EPS $3.30-$3.40, consensus $3.57 05/19/22 VF Corp. reports Q4 adjusted EPS 45c, consensus 46c 05/19/22 Notable companies reporting after market close 01/28/22 VF Corp. backs FY22 EPS view around $3.20, consensus $3.17 PFE Pfizer $51.85 / +1.195 (+2.36%) 05/03/22 Pfizer cuts FY22 adjusted EPS view to $6.25-$6.45 from $6.35-$6.55 05/03/22 Pfizer reports Q1 adjusted EPS $1.62, consensus $1.47 05/02/22 Notable companies reporting before tomorrow's open NOW ServiceNow $437.11 / +10.06 (+2.36%) 04/27/22 ServiceNow sees Q2 subscription revenue $1.670B-$1.675B 04/27/22 ServiceNow reaffirms FY22 subscription revenue view $7.025B-$7.04B 04/27/22 ServiceNow reports Q1 adjusted EPS $1.73, consensus $1.70 04/27/22 Notable companies reporting after market close MTCH Match Group $77.57 / +2.53 (+3.37%) 05/03/22 Match Group sees Q2 revenue $800M-$810M, consensus $835.2M 05/03/22 Match Group reports Q1 EPS 60c, consensus 54c 05/03/22 Notable companies reporting after market close 02/01/22 Match Group sees FY22 revenue up 15%-20% y/y, consensus $3.62B FTNT Fortinet $285.73 / +10.72 (+3.90%) 05/04/22 Fortinet sees Q2 adjusted EPS $1.05-$1.10, consensus $1.13 05/04/22 Fortinet sees FY22 adjusted EPS $5.00-$5.15, consensus $4.96 05/04/22 Fortinet reports Q1 adjusted EPS 94c, consensus 79c 05/04/22 Notable companies reporting after market close PFE FTNT PFE Pfizer $51.85 / +1.195 (+2.36%) 05/19/22 CDC panel backs booster dose for Pfizer COVID vaccine for kids aged 5-11 05/16/22 Pfizer, BioNTech Covid booster for kids 5-11 expected to be authorized, NYT says 05/04/22 FDA says no data support second course of Pfizer's Paxlovid, Bloomberg says 04/26/22 Biden administration to make Covid pills more widely available, WSJ reports FTNT Fortinet $285.73 / +10.72 (+3.90%) 03/14/22 Israeli government sites crash in cyberattack, Haaretz reports VFC PFE NOW MTCH FTNT VFC VF Corp. $46.63 / +2 (+4.48%) 09:13 Today Fly Intel: Pre-market Movers 05/19/22 Fly Intel: After-Hours Movers 04/06/22 What You Missed On Wall Street On Wednesday 04/06/22 What You Missed On Wall Street This Morning PFE Pfizer $51.85 / +1.195 (+2.36%) 05/10/22 Fly Intel: Pre-market Movers 05/03/22 What You Missed On Wall Street On Tuesday NOW ServiceNow $437.11 / +10.06 (+2.36%) 05/18/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 04/27/22 Fly Intel: After-Hours Movers 01/27/22 Wall Street in Fives - Must Read Lists for Thursday 01/27/22 Wall Street in Fives - Must Read Lists at Midday MTCH Match Group $77.57 / +2.53 (+3.37%) 05/10/22 What You Missed On Wall Street On Tuesday 05/10/22 What You Missed On Wall Street This Morning 05/09/22 What You Missed On Wall Street On Monday 05/09/22 What You Missed On Wall Street This Morning FTNT Fortinet $285.73 / +10.72 (+3.90%) 05/05/22 What You Missed On Wall Street On Thursday 05/05/22 What You Missed On Wall Street This Morning 05/05/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 05/04/22 Fly Intel: After-Hours Movers 05/22/22 DDW 2022 05/23/22 50th Annual Global Technology, Media & Communications Conference 06/01/22 50th Annual Technology, Media & Telecom Conference 06/02/22 38th Annual Strategic Decisions Conference 06/03/22 2022 ASCO Annual Meeting 06/06/22 Piper Sandler Events in Conjunction with RSA Conference 08/06/22 Extended PDUFA Date for MYFEMBREE 05/26/22 Pfizer 06/08/22 Match Group, Inc. 06/09/22 ServiceNow, Inc. 06/17/22 Fortinet, Inc. VFC PFE NOW MTCH FTNT VFC VF Corp. $46.63 / +2 (+4.48%) 05/19/22 V F Corp options imply 7.8% move in share price post-earnings 03/07/22 Unusually active option classes on open March 7th PFE Pfizer $51.85 / +1.195 (+2.36%) 04/26/22 Unusually active option classes on open April 26th 04/11/22 Unusually active option classes on open April 11th 04/07/22 Pfizer call volume above normal and directionally bullish 04/06/22 Pfizer call volume above normal and directionally bullish NOW ServiceNow $437.11 / +10.06 (+2.36%) 05/04/22 ServiceNow call volume above normal and directionally bullish 04/28/22 Early notable gainers among liquid option names on April 28th 04/27/22 ServiceNow options imply 8.7% move in share price post-earnings 04/04/22 Early notable gainers among liquid option names on April 4th MTCH Match Group $77.57 / +2.53 (+3.37%) 05/03/22 Match Group options imply 8.6% move in share price post-earnings 04/25/22 Early notable gainers among liquid option names on April 25th 03/14/22 Match Group call volume above normal and directionally bullish 03/11/22 Match Group call volume above normal and directionally bullish FTNT Fortinet $285.73 / +10.72 (+3.90%) 04/07/22 Early notable gainers among liquid option names on April 7th 02/03/22 Fortinet options imply 7.8% move in share price post-earnings 01/19/22 Early notable gainers among liquid option names on January 19th 12/27/21 Early notable gainers among liquid option names on December 27th

Yesterday
Periodicals	CDC panel backs booster dose for Pfizer COVID vaccine for kids aged 5-11 » 15:56 05/19/22 05/19 15:56 05/19/22 15:56 PFE Pfizer $50.41 / + (+0.00%) , BNTX BioNTech $165.98 / +8.82 (+5.61%) A CDC advisory panel has… A CDC advisory panel has voted 11-1, with one abstention, to back a booster dose of the Pfizer (PFE) and BioNTech (BNTX) COVID vaccine for children aged five to eleven years old, according to multiple media reports. ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options PFE BNTX PFE Pfizer $50.41 / + (+0.00%) 05/17/22 Pfizer, BioNTech receive FDA emergency use authorization for child booster 05/17/22 FDA expands eligibility for Pfizer-BioNTech booster to kids 5-11 years old 05/16/22 Mirati Therapeutics appoints Laurie Stelzer as CFO 05/13/22 Pfizer EVP Carapezzi sells 32,908 common shares BNTX BioNTech $165.98 / +8.82 (+5.61%) 05/09/22 BioNTech backs FY22 CapEx view EUR 450M- EUR 550M 05/09/22 BioNTech backs FY22 COVID-19 vaccine revenue view EUR 13B-EUR 17B PFE BNTX PFE Pfizer $50.41 / + (+0.00%) 05/11/22 H.C. Wainwright Biohaven Pharmaceutical downgraded to Neutral from Buy at H.C. Wainwright 05/11/22 Wedbush Global Blood Therapeutics added to Best Ideas List at Wedbush 05/05/22 Stifel Stifel keeps Buy rating on Arvinas, lowers price target to $82 05/04/22 Wells Fargo Pfizer price target lowered to $55 from $60 at Wells Fargo BNTX BioNTech $165.98 / +8.82 (+5.61%) 04/12/22 H.C. Wainwright BioNTech price target lowered to $298 from $339 at H.C. Wainwright 04/11/22 H.C. Wainwright H.C. Wainwright bullish on Matinas as LNC platform attracts BioNTech collab 04/05/22 Canaccord BioNTech price target lowered to $300 from $450 at Canaccord 02/23/22 H.C. Wainwright BioNTech price target lowered to $336 from $366 at H.C. Wainwright PFE BNTX PFE Pfizer $50.41 / + (+0.00%) 05/03/22 Pfizer cuts FY22 adjusted EPS view to $6.25-$6.45 from $6.35-$6.55 05/03/22 Pfizer reports Q1 adjusted EPS $1.62, consensus $1.47 05/02/22 Notable companies reporting before tomorrow's open BNTX BioNTech $165.98 / +8.82 (+5.61%) 05/09/22 BioNTech reports Q1 EPS EUR 14.24 vs. EUR 4.39 last year 03/30/22 BioNTech reports Q4 EPS EUR 12.18 vs. EUR 1.43 last year PFE BNTX PFE Pfizer $50.41 / + (+0.00%) 05/16/22 Pfizer, BioNTech Covid booster for kids 5-11 expected to be authorized, NYT says 05/04/22 FDA says no data support second course of Pfizer's Paxlovid, Bloomberg says 04/26/22 Biden administration to make Covid pills more widely available, WSJ reports 03/28/22 Biden administration plans to offer second booster shots for some, NYT reports BNTX BioNTech $165.98 / +8.82 (+5.61%) 03/23/22 Biden administration eyes new COVID booster shot recommendation, Politico says 03/16/22 J&J's Covid-19 vaccine holding its own against Moderna, Pfizer, NYT reports PFE BNTX PFE Pfizer $50.41 / + (+0.00%) 05/10/22 What You Missed On Wall Street On Tuesday 05/10/22 What You Missed On Wall Street This Morning 05/10/22 Fly Intel: Pre-market Movers 05/03/22 What You Missed On Wall Street On Tuesday BNTX BioNTech $165.98 / +8.82 (+5.61%) 04/14/22 What You Missed On Wall Street On Thursday 04/14/22 What You Missed On Wall Street This Morning 03/30/22 Fly Intel: Pre-market Movers 03/29/22 What You Missed On Wall Street On Tuesday 05/22/22 DDW 2022 05/23/22 8th Annual Berenberg Conference USA 2022 06/02/22 38th Annual Strategic Decisions Conference 06/03/22 2022 ASCO Annual Meeting 08/08/22 BioNTech - BNTX 08/06/22 Extended PDUFA Date for MYFEMBREE 05/19/22 Pfizer 05/26/22 Pfizer 06/01/22 BioNTech SE PFE BNTX PFE Pfizer $50.41 / + (+0.00%) 04/26/22 Unusually active option classes on open April 26th 04/11/22 Unusually active option classes on open April 11th 04/07/22 Pfizer call volume above normal and directionally bullish 04/06/22 Pfizer call volume above normal and directionally bullish BNTX BioNTech $165.98 / +8.82 (+5.61%) 03/30/22 Unusually active option classes on open March 30th 03/01/22 BioNTech SE put volume heavy and directionally bearish 02/08/22 BioNTech SE put volume heavy and directionally bearish 12/13/21 BioNTech SE call volume above normal and directionally bullish
Conference/Events	Pfizer management to meet with Oppenheimer » 04:55 05/19/22 05/19 04:55 05/19/22 04:55 PFE Pfizer $50.41 / -0.93 (-1.81%) Meeting to be held in New… Meeting to be held in New York on May 19 hosted by Oppenheimer. ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options PFE Pfizer $50.41 / -0.93 (-1.81%) 05/17/22 Pfizer, BioNTech receive FDA emergency use authorization for child booster 05/17/22 FDA expands eligibility for Pfizer-BioNTech booster to kids 5-11 years old 05/16/22 Mirati Therapeutics appoints Laurie Stelzer as CFO 05/13/22 Pfizer EVP Carapezzi sells 32,908 common shares PFE Pfizer $50.41 / -0.93 (-1.81%) 05/11/22 H.C. Wainwright Biohaven Pharmaceutical downgraded to Neutral from Buy at H.C. Wainwright 05/11/22 Wedbush Global Blood Therapeutics added to Best Ideas List at Wedbush 05/05/22 Stifel Stifel keeps Buy rating on Arvinas, lowers price target to $82 05/04/22 Wells Fargo Pfizer price target lowered to $55 from $60 at Wells Fargo PFE Pfizer $50.41 / -0.93 (-1.81%) 05/03/22 Pfizer cuts FY22 adjusted EPS view to $6.25-$6.45 from $6.35-$6.55 05/03/22 Pfizer reports Q1 adjusted EPS $1.62, consensus $1.47 05/02/22 Notable companies reporting before tomorrow's open PFE Pfizer $50.41 / -0.93 (-1.81%) 05/16/22 Pfizer, BioNTech Covid booster for kids 5-11 expected to be authorized, NYT says 05/04/22 FDA says no data support second course of Pfizer's Paxlovid, Bloomberg says 04/26/22 Biden administration to make Covid pills more widely available, WSJ reports 03/28/22 Biden administration plans to offer second booster shots for some, NYT reports PFE Pfizer $50.41 / -0.93 (-1.81%) 05/10/22 What You Missed On Wall Street On Tuesday 05/10/22 What You Missed On Wall Street This Morning 05/10/22 Fly Intel: Pre-market Movers 05/03/22 What You Missed On Wall Street On Tuesday 05/22/22 DDW 2022 06/02/22 38th Annual Strategic Decisions Conference 06/03/22 2022 ASCO Annual Meeting 08/06/22 Extended PDUFA Date for MYFEMBREE 05/19/22 Pfizer 05/26/22 Pfizer PFE Pfizer $50.41 / -0.93 (-1.81%) 04/26/22 Unusually active option classes on open April 26th 04/11/22 Unusually active option classes on open April 11th 04/07/22 Pfizer call volume above normal and directionally bullish 04/06/22 Pfizer call volume above normal and directionally bullish

Tuesday
Hot Stocks	Pfizer, BioNTech receive FDA emergency use authorization for child booster » 11:44 05/17/22 05/17 11:44 05/17/22 11:44 PFE Pfizer $51.32 / +0.64 (+1.26%) , BNTX BioNTech $159.20 / +7.99 (+5.28%) Pfizer (PFE) and BioNTech… Pfizer (PFE) and BioNTech (BNTX) announced the Food and Drug Administration expanded emergency use authorization to include a booster dose after completion of the primary series of the Pfizer-BioNTech COVID-19 Vaccine in children five through 11 years of age. The booster dose is given at least five months after the second dose of the two-dose primary series and is the same 10-microgram dose of the Pfizer-BioNTech COVID-19 Vaccine. The companies have already submitted an application to the European Medicines Agency for a booster dose in this age group and are planning to file with other regulatory agencies around the world. ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options PFE BNTX PFE Pfizer $51.32 / +0.64 (+1.26%) 05/17/22 FDA expands eligibility for Pfizer-BioNTech booster to kids 5-11 years old 05/16/22 Mirati Therapeutics appoints Laurie Stelzer as CFO 05/13/22 Pfizer EVP Carapezzi sells 32,908 common shares 05/10/22 Pfizer to acquire Biohaven Pharmaceuticals for $148.50 per share BNTX BioNTech $159.20 / +7.99 (+5.28%) 05/09/22 BioNTech backs FY22 CapEx view EUR 450M- EUR 550M 05/09/22 BioNTech backs FY22 COVID-19 vaccine revenue view EUR 13B-EUR 17B 05/02/22 FDA announces tentative advisory committee meetings on COVID-19 vaccines PFE BNTX PFE Pfizer $51.32 / +0.64 (+1.26%) 05/11/22 H.C. Wainwright Biohaven Pharmaceutical downgraded to Neutral from Buy at H.C. Wainwright 05/11/22 Wedbush Global Blood Therapeutics added to Best Ideas List at Wedbush 05/05/22 Stifel Stifel keeps Buy rating on Arvinas, lowers price target to $82 05/04/22 Wells Fargo Pfizer price target lowered to $55 from $60 at Wells Fargo BNTX BioNTech $159.20 / +7.99 (+5.28%) 04/12/22 H.C. Wainwright BioNTech price target lowered to $298 from $339 at H.C. Wainwright 04/11/22 H.C. Wainwright H.C. Wainwright bullish on Matinas as LNC platform attracts BioNTech collab 04/05/22 Canaccord BioNTech price target lowered to $300 from $450 at Canaccord 02/23/22 H.C. Wainwright BioNTech price target lowered to $336 from $366 at H.C. Wainwright PFE BNTX PFE Pfizer $51.32 / +0.64 (+1.26%) 05/03/22 Pfizer cuts FY22 adjusted EPS view to $6.25-$6.45 from $6.35-$6.55 05/03/22 Pfizer reports Q1 adjusted EPS $1.62, consensus $1.47 05/02/22 Notable companies reporting before tomorrow's open BNTX BioNTech $159.20 / +7.99 (+5.28%) 05/09/22 BioNTech reports Q1 EPS EUR 14.24 vs. EUR 4.39 last year 03/30/22 BioNTech reports Q4 EPS EUR 12.18 vs. EUR 1.43 last year PFE BNTX PFE Pfizer $51.32 / +0.64 (+1.26%) 05/16/22 Pfizer, BioNTech Covid booster for kids 5-11 expected to be authorized, NYT says 05/04/22 FDA says no data support second course of Pfizer's Paxlovid, Bloomberg says 04/26/22 Biden administration to make Covid pills more widely available, WSJ reports 03/28/22 Biden administration plans to offer second booster shots for some, NYT reports BNTX BioNTech $159.20 / +7.99 (+5.28%) 03/23/22 Biden administration eyes new COVID booster shot recommendation, Politico says 03/16/22 J&J's Covid-19 vaccine holding its own against Moderna, Pfizer, NYT reports PFE BNTX PFE Pfizer $51.32 / +0.64 (+1.26%) 05/10/22 What You Missed On Wall Street On Tuesday 05/10/22 What You Missed On Wall Street This Morning 05/10/22 Fly Intel: Pre-market Movers 05/03/22 What You Missed On Wall Street On Tuesday BNTX BioNTech $159.20 / +7.99 (+5.28%) 04/14/22 What You Missed On Wall Street On Thursday 04/14/22 What You Missed On Wall Street This Morning 03/30/22 Fly Intel: Pre-market Movers 03/29/22 What You Missed On Wall Street On Tuesday 05/22/22 DDW 2022 05/23/22 8th Annual Berenberg Conference USA 2022 06/02/22 38th Annual Strategic Decisions Conference 06/03/22 2022 ASCO Annual Meeting 08/08/22 BioNTech - BNTX 08/06/22 Extended PDUFA Date for MYFEMBREE 05/19/22 Pfizer 05/26/22 Pfizer 06/01/22 BioNTech SE PFE BNTX PFE Pfizer $51.32 / +0.64 (+1.26%) 04/26/22 Unusually active option classes on open April 26th 04/11/22 Unusually active option classes on open April 11th 04/07/22 Pfizer call volume above normal and directionally bullish 04/06/22 Pfizer call volume above normal and directionally bullish BNTX BioNTech $159.20 / +7.99 (+5.28%) 03/30/22 Unusually active option classes on open March 30th 03/01/22 BioNTech SE put volume heavy and directionally bearish 02/08/22 BioNTech SE put volume heavy and directionally bearish 12/13/21 BioNTech SE call volume above normal and directionally bullish
Hot Stocks	FDA expands eligibility for Pfizer-BioNTech booster to kids 5-11 years old » 10:16 05/17/22 05/17 10:16 05/17/22 10:16 PFE Pfizer $50.69 / +0.01 (+0.02%) , BNTX BioNTech $156.13 / +4.92 (+3.25%) The U.S. Food and Drug… The U.S. Food and Drug Administration amended the emergency use authorization for the Pfizer (PFE) BioNTech (BNTX) COVID-19 Vaccine, authorizing the use of a single booster dose for administration to individuals 5 through 11 years of age at least five months after completion of a primary series with the Pfizer-BioNTech COVID-19 Vaccine. Peter Marks, M.D., Ph.D., director of the FDA's Center for Biologics Evaluation and Research, said, "Since authorizing the vaccine for children down to 5 years of age in October 2021, emerging data suggest that vaccine effectiveness against COVID-19 wanes after the second dose of the vaccine in all authorized populations. The FDA has determined that the known and potential benefits of a single booster dose of the Pfizer-BioNTech COVID-19 Vaccine for children 5 through 11 years of age at least five months after completing a primary series outweigh its known and potential risks and that a booster dose can help provide continued protection against COVID-19 in this and older age groups." Reference Link ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options PFE BNTX PFE Pfizer $50.69 / +0.01 (+0.02%) 05/16/22 Mirati Therapeutics appoints Laurie Stelzer as CFO 05/13/22 Pfizer EVP Carapezzi sells 32,908 common shares 05/10/22 Pfizer to acquire Biohaven Pharmaceuticals for $148.50 per share 05/10/22 Pfizer to acquire Biohaven Pharmaceuticals for $148.50 per share in cash BNTX BioNTech $156.13 / +4.92 (+3.25%) 05/09/22 BioNTech backs FY22 CapEx view EUR 450M- EUR 550M 05/09/22 BioNTech backs FY22 COVID-19 vaccine revenue view EUR 13B-EUR 17B 05/02/22 FDA announces tentative advisory committee meetings on COVID-19 vaccines 04/26/22 Pfizer, BioNTech ask FDA to authorize booster dose for children ages 5-11 PFE BNTX PFE Pfizer $50.69 / +0.01 (+0.02%) 05/11/22 H.C. Wainwright Biohaven Pharmaceutical downgraded to Neutral from Buy at H.C. Wainwright 05/11/22 Wedbush Global Blood Therapeutics added to Best Ideas List at Wedbush 05/05/22 Stifel Stifel keeps Buy rating on Arvinas, lowers price target to $82 05/04/22 Wells Fargo Pfizer price target lowered to $55 from $60 at Wells Fargo BNTX BioNTech $156.13 / +4.92 (+3.25%) 04/12/22 H.C. Wainwright BioNTech price target lowered to $298 from $339 at H.C. Wainwright 04/11/22 H.C. Wainwright H.C. Wainwright bullish on Matinas as LNC platform attracts BioNTech collab 04/05/22 Canaccord BioNTech price target lowered to $300 from $450 at Canaccord 02/23/22 H.C. Wainwright BioNTech price target lowered to $336 from $366 at H.C. Wainwright PFE BNTX PFE Pfizer $50.69 / +0.01 (+0.02%) 05/03/22 Pfizer cuts FY22 adjusted EPS view to $6.25-$6.45 from $6.35-$6.55 05/03/22 Pfizer reports Q1 adjusted EPS $1.62, consensus $1.47 05/02/22 Notable companies reporting before tomorrow's open BNTX BioNTech $156.13 / +4.92 (+3.25%) 05/09/22 BioNTech reports Q1 EPS EUR 14.24 vs. EUR 4.39 last year 03/30/22 BioNTech reports Q4 EPS EUR 12.18 vs. EUR 1.43 last year PFE BNTX PFE Pfizer $50.69 / +0.01 (+0.02%) 05/16/22 Pfizer, BioNTech Covid booster for kids 5-11 expected to be authorized, NYT says 05/04/22 FDA says no data support second course of Pfizer's Paxlovid, Bloomberg says 04/26/22 Biden administration to make Covid pills more widely available, WSJ reports 03/28/22 Biden administration plans to offer second booster shots for some, NYT reports BNTX BioNTech $156.13 / +4.92 (+3.25%) 03/23/22 Biden administration eyes new COVID booster shot recommendation, Politico says 03/16/22 J&J's Covid-19 vaccine holding its own against Moderna, Pfizer, NYT reports PFE BNTX PFE Pfizer $50.69 / +0.01 (+0.02%) 05/10/22 What You Missed On Wall Street On Tuesday 05/10/22 What You Missed On Wall Street This Morning 05/10/22 Fly Intel: Pre-market Movers 05/03/22 What You Missed On Wall Street On Tuesday BNTX BioNTech $156.13 / +4.92 (+3.25%) 04/14/22 What You Missed On Wall Street On Thursday 04/14/22 What You Missed On Wall Street This Morning 03/30/22 Fly Intel: Pre-market Movers 03/29/22 What You Missed On Wall Street On Tuesday 05/22/22 DDW 2022 05/23/22 8th Annual Berenberg Conference USA 2022 06/02/22 38th Annual Strategic Decisions Conference 06/03/22 2022 ASCO Annual Meeting 08/08/22 BioNTech - BNTX 08/06/22 Extended PDUFA Date for MYFEMBREE 05/19/22 Pfizer 05/26/22 Pfizer 06/01/22 BioNTech SE PFE BNTX PFE Pfizer $50.69 / +0.01 (+0.02%) 04/26/22 Unusually active option classes on open April 26th 04/11/22 Unusually active option classes on open April 11th 04/07/22 Pfizer call volume above normal and directionally bullish 04/06/22 Pfizer call volume above normal and directionally bullish BNTX BioNTech $156.13 / +4.92 (+3.25%) 03/30/22 Unusually active option classes on open March 30th 03/01/22 BioNTech SE put volume heavy and directionally bearish 02/08/22 BioNTech SE put volume heavy and directionally bearish 12/13/21 BioNTech SE call volume above normal and directionally bullish

Monday
Conference/Events	Pfizer management to meet with Oppenheimer » 16:55 05/16/22 05/16 16:55 05/16/22 16:55 PFE Pfizer $50.68 / +0.78 (+1.56%) Meeting to be held in New… Meeting to be held in New York on May 19 hosted by Oppenheimer. ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options PFE Pfizer $50.68 / +0.78 (+1.56%) 05/16/22 Mirati Therapeutics appoints Laurie Stelzer as CFO 05/13/22 Pfizer EVP Carapezzi sells 32,908 common shares 05/10/22 Pfizer to acquire Biohaven Pharmaceuticals for $148.50 per share 05/10/22 Pfizer to acquire Biohaven Pharmaceuticals for $148.50 per share in cash PFE Pfizer $50.68 / +0.78 (+1.56%) 05/11/22 H.C. Wainwright Biohaven Pharmaceutical downgraded to Neutral from Buy at H.C. Wainwright 05/11/22 Wedbush Global Blood Therapeutics added to Best Ideas List at Wedbush 05/05/22 Stifel Stifel keeps Buy rating on Arvinas, lowers price target to $82 05/04/22 Wells Fargo Pfizer price target lowered to $55 from $60 at Wells Fargo PFE Pfizer $50.68 / +0.78 (+1.56%) 05/03/22 Pfizer cuts FY22 adjusted EPS view to $6.25-$6.45 from $6.35-$6.55 05/03/22 Pfizer reports Q1 adjusted EPS $1.62, consensus $1.47 05/02/22 Notable companies reporting before tomorrow's open PFE Pfizer $50.68 / +0.78 (+1.56%) 05/16/22 Pfizer, BioNTech Covid booster for kids 5-11 expected to be authorized, NYT says 05/04/22 FDA says no data support second course of Pfizer's Paxlovid, Bloomberg says 04/26/22 Biden administration to make Covid pills more widely available, WSJ reports 03/28/22 Biden administration plans to offer second booster shots for some, NYT reports PFE Pfizer $50.68 / +0.78 (+1.56%) 05/10/22 What You Missed On Wall Street On Tuesday 05/10/22 What You Missed On Wall Street This Morning 05/10/22 Fly Intel: Pre-market Movers 05/03/22 What You Missed On Wall Street On Tuesday 05/16/22 25th Annual Meeting of ASGCT 05/22/22 DDW 2022 06/02/22 38th Annual Strategic Decisions Conference 06/03/22 2022 ASCO Annual Meeting 08/06/22 Extended PDUFA Date for MYFEMBREE 05/19/22 Pfizer 05/26/22 Pfizer PFE Pfizer $50.68 / +0.78 (+1.56%) 04/26/22 Unusually active option classes on open April 26th 04/11/22 Unusually active option classes on open April 11th 04/07/22 Pfizer call volume above normal and directionally bullish 04/06/22 Pfizer call volume above normal and directionally bullish
Hot Stocks	Mirati Therapeutics appoints Laurie Stelzer as CFO » 16:33 05/16/22 05/16 16:33 05/16/22 16:33 MRTX Mirati Therapeutics $56.42 / -0.36 (-0.63%) , PFE Pfizer $50.68 / +0.78 (+1.56%) , TAK Takeda Pharmaceutical $14.27 / -0.085 (-0.59%) Mirati Therapeutics… Mirati Therapeutics (MRTX) the appointment of Laurie Stelzer as the Company's CFO effective May 16. Laurie will report to the Company's CEO, David Meek. Laurie joins the Company most recently from Arena Pharmaceuticals, acquired by Pfizer (PFE), where she served as Executive Vice President and CFO since 2020. She brings 25 years of biopharma industry experience to her role in leading the company's finance functions. Prior to joining Arena, Laurie was the CFO at Halozyme Therapeutics where she led the finance, information technology, business development, project management and site operations organizations. Prior to joining Halozyme, Laurie held senior management roles at Shire, acquired by Takeda (TAK), including Senior Vice President of Finance, Division CFO for the Regenerative Medicine Division, and Head of Investor Relations. Previously she held positions of increasing responsibility during her fifteen-year career at Amgen, spanning the areas of finance, treasury, global accounting, and international/emerging markets. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options TAK PFE MRTX TAK Takeda Pharmaceutical $14.27 / -0.085 (-0.59%) 04/28/22 Centogene expands partnership with Takeda Pharmaceutical 04/19/22 Takeda Pharmaceutical receives approval from Japan MHLW for Nuvaxovid 04/12/22 Takeda Pharmaceutical announces SHP643-301 study meets objectives 03/28/22 Takeda announces Takhzyro approved in Japan for acute HAE prophylaxis PFE Pfizer $50.68 / +0.78 (+1.56%) 05/13/22 Pfizer EVP Carapezzi sells 32,908 common shares 05/10/22 Pfizer to acquire Biohaven Pharmaceuticals for $148.50 per share 05/10/22 Pfizer to acquire Biohaven Pharmaceuticals for $148.50 per share in cash 05/06/22 Myovant Sciences and Pfizer provide update on Myfembree sNDA in endometriosis MRTX Mirati Therapeutics $56.42 / -0.36 (-0.63%) 03/21/22 AnaptysBio names Daniel Faga as interim CEO, succeeding Hamza Suria 02/15/22 Mirati Therapeutics says FDA accepts NDA for adagrasib 01/21/22 Mirati Therapeutics presents results from Phase 2 cohort of KRYSTAL-1 study 12/15/21 Surface Oncology appoints Torres as chair of board of directors MRTX PFE TAK MRTX Mirati Therapeutics $56.42 / -0.36 (-0.63%) 05/05/22 Stifel ASCO sets up as 'downside-biased' for Mirati investors, says Stifel 05/05/22 Citi Mirati Therapeutics price target lowered to $208 from $227 at Citi 03/02/22 Citi Mirati Therapeutics price target lowered to $227 from $244 at Citi 03/01/22 BMO Capital Mirati Therapeutics price target lowered to $130 from $187 at BMO Capital PFE Pfizer $50.68 / +0.78 (+1.56%) 05/11/22 H.C. Wainwright Biohaven Pharmaceutical downgraded to Neutral from Buy at H.C. Wainwright 05/11/22 Wedbush Global Blood Therapeutics added to Best Ideas List at Wedbush 05/05/22 Stifel Stifel keeps Buy rating on Arvinas, lowers price target to $82 05/04/22 Wells Fargo Pfizer price target lowered to $55 from $60 at Wells Fargo TAK Takeda Pharmaceutical $14.27 / -0.085 (-0.59%) 05/13/22 BTIG Poseida Therapeutics price target lowered to $20 from $40 at BTIG 03/31/22 Canaccord Canaccord starts Morphic at Buy, sees potential to take share from Takeda 02/11/22 BTIG Protagonist Therapeutics initiated with a Buy at BTIG 02/11/22 BTIG Morphic initiated with a Buy at BTIG PFE MRTX PFE Pfizer $50.68 / +0.78 (+1.56%) 05/03/22 Pfizer cuts FY22 adjusted EPS view to $6.25-$6.45 from $6.35-$6.55 05/03/22 Pfizer reports Q1 adjusted EPS $1.62, consensus $1.47 05/02/22 Notable companies reporting before tomorrow's open MRTX Mirati Therapeutics $56.42 / -0.36 (-0.63%) 02/28/22 Mirati Therapeutics reports Q4 EPS ($3.72), consensus ($3.00) 02/28/22 Mirati Therapeutics reports Q4 EPS ($3072), consensus ($3.00) 11 Nov TAK PFE TAK Takeda Pharmaceutical $14.27 / -0.085 (-0.59%) 04/18/22 Japan on verge of approving Novavax COVID vaccine, Nikkei reports PFE Pfizer $50.68 / +0.78 (+1.56%) 05/16/22 Pfizer, BioNTech Covid booster for kids 5-11 expected to be authorized, NYT says 05/04/22 FDA says no data support second course of Pfizer's Paxlovid, Bloomberg says 04/26/22 Biden administration to make Covid pills more widely available, WSJ reports 03/28/22 Biden administration plans to offer second booster shots for some, NYT reports TAK PFE MRTX TAK Takeda Pharmaceutical $14.27 / -0.085 (-0.59%) 01/19/22 Meet Sangamo: Fly exclusive interview with CEO Sandy Macrae, COO Mark McClung PFE Pfizer $50.68 / +0.78 (+1.56%) 05/10/22 What You Missed On Wall Street On Tuesday 05/10/22 What You Missed On Wall Street This Morning 05/10/22 Fly Intel: Pre-market Movers 05/03/22 What You Missed On Wall Street On Tuesday MRTX Mirati Therapeutics $56.42 / -0.36 (-0.63%) 05/06/22 Proven algorithm says sell these stocks now 05/16/22 25th Annual Meeting of ASGCT 05/22/22 DDW 2022 06/02/22 38th Annual Strategic Decisions Conference 06/03/22 2022 ASCO Annual Meeting 08/06/22 Extended PDUFA Date for MYFEMBREE 12/14/22 PDUFA Date for Adagrasib 05/19/22 Pfizer 05/26/22 Pfizer PFE PFE Pfizer $50.68 / +0.78 (+1.56%) 04/26/22 Unusually active option classes on open April 26th 04/11/22 Unusually active option classes on open April 11th 04/07/22 Pfizer call volume above normal and directionally bullish 04/06/22 Pfizer call volume above normal and directionally bullish
Periodicals	Pfizer, BioNTech Covid booster for kids 5-11 expected to be authorized, NYT says » 15:59 05/16/22 05/16 15:59 05/16/22 15:59 PFE Pfizer $50.67 / +0.77 (+1.54%) , BNTX BioNTech $151.47 / -7.33 (-4.62%) The Pfizer (PFE)-BioNTech… The Pfizer (PFE)-BioNTech (BNTX) Covid-19 vaccine booster shot is expected to be authorized by the FDA for children ages 5 to 11, The New York Times' Sharon LaFraniere reports, citing multiple people familiar with the plan. Last month, the companies said that the booster significantly increased the level of neutralizing antibodies against both the original version of the virus and the omicron variant in a small clinical trial of 140 children. A meeting of outside vaccine experts on an advisory committee to the Centers for Disease Control and Prevention has been scheduled for Thursday, according to the report. Reference Link ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options PFE BNTX PFE Pfizer $50.67 / +0.77 (+1.54%) 05/13/22 Pfizer EVP Carapezzi sells 32,908 common shares 05/10/22 Pfizer to acquire Biohaven Pharmaceuticals for $148.50 per share 05/10/22 Pfizer to acquire Biohaven Pharmaceuticals for $148.50 per share in cash 05/06/22 Myovant Sciences and Pfizer provide update on Myfembree sNDA in endometriosis BNTX BioNTech $151.47 / -7.33 (-4.62%) 05/09/22 BioNTech backs FY22 CapEx view EUR 450M- EUR 550M 05/09/22 BioNTech backs FY22 COVID-19 vaccine revenue view EUR 13B-EUR 17B 05/02/22 FDA announces tentative advisory committee meetings on COVID-19 vaccines 04/26/22 Pfizer, BioNTech ask FDA to authorize booster dose for children ages 5-11 PFE BNTX PFE Pfizer $50.67 / +0.77 (+1.54%) 05/11/22 H.C. Wainwright Biohaven Pharmaceutical downgraded to Neutral from Buy at H.C. Wainwright 05/11/22 Wedbush Global Blood Therapeutics added to Best Ideas List at Wedbush 05/05/22 Stifel Stifel keeps Buy rating on Arvinas, lowers price target to $82 05/04/22 Wells Fargo Pfizer price target lowered to $55 from $60 at Wells Fargo BNTX BioNTech $151.47 / -7.33 (-4.62%) 04/12/22 H.C. Wainwright BioNTech price target lowered to $298 from $339 at H.C. Wainwright 04/11/22 H.C. Wainwright H.C. Wainwright bullish on Matinas as LNC platform attracts BioNTech collab 04/05/22 Canaccord BioNTech price target lowered to $300 from $450 at Canaccord 02/23/22 H.C. Wainwright BioNTech price target lowered to $336 from $366 at H.C. Wainwright PFE BNTX PFE Pfizer $50.67 / +0.77 (+1.54%) 05/03/22 Pfizer cuts FY22 adjusted EPS view to $6.25-$6.45 from $6.35-$6.55 05/03/22 Pfizer reports Q1 adjusted EPS $1.62, consensus $1.47 05/02/22 Notable companies reporting before tomorrow's open BNTX BioNTech $151.47 / -7.33 (-4.62%) 05/09/22 BioNTech reports Q1 EPS EUR 14.24 vs. EUR 4.39 last year 03/30/22 BioNTech reports Q4 EPS EUR 12.18 vs. EUR 1.43 last year PFE BNTX PFE Pfizer $50.67 / +0.77 (+1.54%) 05/04/22 FDA says no data support second course of Pfizer's Paxlovid, Bloomberg says 04/26/22 Biden administration to make Covid pills more widely available, WSJ reports 03/28/22 Biden administration plans to offer second booster shots for some, NYT reports 03/27/22 Pfizer, Moderna face shareholder pressure to broaden vaccine access, WSJ says BNTX BioNTech $151.47 / -7.33 (-4.62%) 03/23/22 Biden administration eyes new COVID booster shot recommendation, Politico says 03/16/22 J&J's Covid-19 vaccine holding its own against Moderna, Pfizer, NYT reports 03/15/22 Pfizer to seek second shot authorization for 65 and older, Washington Post says PFE BNTX PFE Pfizer $50.67 / +0.77 (+1.54%) 05/10/22 What You Missed On Wall Street On Tuesday 05/10/22 What You Missed On Wall Street This Morning 05/10/22 Fly Intel: Pre-market Movers 05/03/22 What You Missed On Wall Street On Tuesday BNTX BioNTech $151.47 / -7.33 (-4.62%) 04/14/22 What You Missed On Wall Street On Thursday 04/14/22 What You Missed On Wall Street This Morning 03/30/22 Fly Intel: Pre-market Movers 03/29/22 What You Missed On Wall Street On Tuesday 05/16/22 25th Annual Meeting of ASGCT 05/22/22 DDW 2022 05/23/22 8th Annual Berenberg Conference USA 2022 06/02/22 38th Annual Strategic Decisions Conference 06/03/22 2022 ASCO Annual Meeting 08/08/22 BioNTech - BNTX 08/06/22 Extended PDUFA Date for MYFEMBREE 05/19/22 Pfizer 05/26/22 Pfizer 06/01/22 BioNTech SE PFE BNTX PFE Pfizer $50.67 / +0.77 (+1.54%) 04/26/22 Unusually active option classes on open April 26th 04/11/22 Unusually active option classes on open April 11th 04/07/22 Pfizer call volume above normal and directionally bullish 04/06/22 Pfizer call volume above normal and directionally bullish BNTX BioNTech $151.47 / -7.33 (-4.62%) 03/30/22 Unusually active option classes on open March 30th 03/01/22 BioNTech SE put volume heavy and directionally bearish 02/08/22 BioNTech SE put volume heavy and directionally bearish 12/13/21 BioNTech SE call volume above normal and directionally bullish

Over a week ago
Hot Stocks	Pfizer EVP Carapezzi sells 32,908 common shares » 17:41 05/13/22 05/13 17:41 05/13/22 17:41 PFE Pfizer $49.90 / -0.52 (-1.03%) In a regulatory filing,… In a regulatory filing, Pfizer executive VP William Carapezzi, Jr. disclosed the sale of 32,908 common shares of the company on May 12 at a price of $50 per share. ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options PFE Pfizer $49.90 / -0.52 (-1.03%) 05/10/22 Pfizer to acquire Biohaven Pharmaceuticals for $148.50 per share 05/10/22 Pfizer to acquire Biohaven Pharmaceuticals for $148.50 per share in cash 05/06/22 Myovant Sciences and Pfizer provide update on Myfembree sNDA in endometriosis 05/03/22 Pfizer CEO says 'delivering on our production commitments for Paxlovid' PFE Pfizer $49.90 / -0.52 (-1.03%) 05/11/22 H.C. Wainwright Biohaven Pharmaceutical downgraded to Neutral from Buy at H.C. Wainwright 05/11/22 Wedbush Global Blood Therapeutics added to Best Ideas List at Wedbush 05/05/22 Stifel Stifel keeps Buy rating on Arvinas, lowers price target to $82 05/04/22 Wells Fargo Pfizer price target lowered to $55 from $60 at Wells Fargo PFE Pfizer $49.90 / -0.52 (-1.03%) 05/03/22 Pfizer cuts FY22 adjusted EPS view to $6.25-$6.45 from $6.35-$6.55 05/03/22 Pfizer reports Q1 adjusted EPS $1.62, consensus $1.47 05/02/22 Notable companies reporting before tomorrow's open PFE Pfizer $49.90 / -0.52 (-1.03%) 05/04/22 FDA says no data support second course of Pfizer's Paxlovid, Bloomberg says 04/26/22 Biden administration to make Covid pills more widely available, WSJ reports 03/28/22 Biden administration plans to offer second booster shots for some, NYT reports 03/27/22 Pfizer, Moderna face shareholder pressure to broaden vaccine access, WSJ says PFE Pfizer $49.90 / -0.52 (-1.03%) 05/10/22 What You Missed On Wall Street On Tuesday 05/10/22 What You Missed On Wall Street This Morning 05/10/22 Fly Intel: Pre-market Movers 05/03/22 What You Missed On Wall Street On Tuesday 05/13/22 AUA 2022 05/22/22 DDW 2022 06/02/22 38th Annual Strategic Decisions Conference 06/03/22 2022 ASCO Annual Meeting 08/06/22 Extended PDUFA Date for MYFEMBREE 05/19/22 Pfizer 05/26/22 Pfizer PFE Pfizer $49.90 / -0.52 (-1.03%) 04/26/22 Unusually active option classes on open April 26th 04/11/22 Unusually active option classes on open April 11th 04/07/22 Pfizer call volume above normal and directionally bullish 04/06/22 Pfizer call volume above normal and directionally bullish
Downgrade	Biohaven Pharmaceutical downgraded to Neutral from Buy at H.C. Wainwright » 08:55 05/11/22 05/11 08:55 05/11/22 08:55 BHVN Biohaven Pharmaceutical / + , PFE Pfizer $49.48 / +0.79 (+1.62%) H.C. Wainwright analyst… H.C. Wainwright analyst Douglas Tsao downgraded Biohaven Pharmaceutical (BHVN) to Neutral from Buy with a $148.50 price target after the company announced that it agreed to be acquired by Pfizer (PFE). The deal "does not come as a big surprise to us," said Tsao, who called Pfizer a "natural acquirer" given the companies' existing commercial partnership. He does not expect another bidder to emerge, Tsao added. ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options PFE BHVN PFE Pfizer $49.48 / +0.79 (+1.62%) 05/10/22 Pfizer to acquire Biohaven Pharmaceuticals for $148.50 per share in cash 05/06/22 Myovant Sciences and Pfizer provide update on Myfembree sNDA in endometriosis 05/03/22 Pfizer CEO says 'delivering on our production commitments for Paxlovid' BHVN Biohaven Pharmaceutical / + 05/10/22 Biohaven Pharmaceutical rises 70.2% 05/10/22 Biohaven Pharmaceutical rises 70.8% 05/10/22 Biohaven Pharmaceutical rises 70.7% 05/10/22 Pfizer to acquire Biohaven Pharmaceuticals for $148.50 per share BHVN PFE BHVN Biohaven Pharmaceutical / + 05/11/22 Wedbush Global Blood Therapeutics added to Best Ideas List at Wedbush 05/02/22 Piper Sandler Piper sees 'outright misinformation' on Biohaven, says buy shares 04/22/22 Piper Sandler Biohaven widening lead over AbbVie in migraine, says Piper Sandler 03/03/22 Mizuho Biohaven Pharmaceutical price target raised to $154 from $144 at Mizuho PFE Pfizer $49.48 / +0.79 (+1.62%) 05/05/22 Stifel Stifel keeps Buy rating on Arvinas, lowers price target to $82 05/04/22 Wells Fargo Pfizer price target lowered to $55 from $60 at Wells Fargo 05/03/22 RBC Capital Clinical hold being lifted a 'clear positive' for Sangamo, says RBC Capital PFE BHVN PFE Pfizer $49.48 / +0.79 (+1.62%) 05/03/22 Pfizer cuts FY22 adjusted EPS view to $6.25-$6.45 from $6.35-$6.55 05/03/22 Pfizer reports Q1 adjusted EPS $1.62, consensus $1.47 05/02/22 Notable companies reporting before tomorrow's open BHVN Biohaven Pharmaceutical / + 05/10/22 Biohaven Pharmaceutical sees 2022 net product sales $825M-$900M 05/10/22 Biohaven Pharmaceutical reports Q1 EPS ($2.97), consensus ($2.53) 02/25/22 Biohaven Pharmaceutical reports Q4 adjusted EPS ($2.32), consensus ($2.04) PFE BHVN PFE Pfizer $49.48 / +0.79 (+1.62%) 05/04/22 FDA says no data support second course of Pfizer's Paxlovid, Bloomberg says 04/26/22 Biden administration to make Covid pills more widely available, WSJ reports 03/28/22 Biden administration plans to offer second booster shots for some, NYT reports 03/27/22 Pfizer, Moderna face shareholder pressure to broaden vaccine access, WSJ says BHVN Biohaven Pharmaceutical / + 01/13/22 Biogen working with Goldman to explore possible acquisitions, STAT says PFE BHVN PFE Pfizer $49.48 / +0.79 (+1.62%) 05/03/22 What You Missed On Wall Street On Tuesday BHVN Biohaven Pharmaceutical / + 05/10/22 What You Missed On Wall Street On Tuesday 05/10/22 What You Missed On Wall Street This Morning 05/10/22 Fly Intel: Pre-market Movers 01/13/22 Wall Street in Fives - Must Read Lists for Thursday 05/13/22 AUA 2022 05/22/22 DDW 2022 06/02/22 38th Annual Strategic Decisions Conference 06/03/22 2022 ASCO Annual Meeting 05/11/22 Biohaven Pharmaceutical - BHVN 05/19/22 Pfizer 05/26/22 Pfizer PFE PFE Pfizer $49.48 / +0.79 (+1.62%) 04/26/22 Unusually active option classes on open April 26th 04/11/22 Unusually active option classes on open April 11th 04/07/22 Pfizer call volume above normal and directionally bullish 04/06/22 Pfizer call volume above normal and directionally bullish

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial